NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson1 (NYSE: JNJ) announced today that it has successfully completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics to secure the global rights to NM26, a novel, investigational first-in-class bispecific antibody, in an all-cash transaction of approximately $1.25 billion, as announced on May 28, 2024..

新泽西州新不伦瑞克市（商业新闻短讯）--强生公司（纽约证券交易所：JNJ）今天宣布，它已成功完成收购Yellow Jersey，Numab Therapeutics的一家分拆子公司，以确保NM26（一种新型的，研究性的一流双特异性抗体）的全球权利，该交易于2024年5月28日宣布，金额约为12.5亿美元。。

NM26, which is ready to enter Phase 2 studies in atopic dermatitis (AD), targets two clinically proven pathways, IL-4R alpha subunit (IL-4Rα) and IL-31, which trigger Th2-mediated skin inflammation and skin itch, respectively.

NM26准备进入特应性皮炎（AD）的2期研究，靶向两种临床证实的途径，IL-4Rα亚基（IL-4Rα）和IL-31，它们分别引发Th2介导的皮肤炎症和皮肤瘙痒。

“NM26 is designed to help different subpopulations of patients by targeting two disease-driving pathways, which is key when treating a heterogeneous disease like AD,” said David Lee, Global Immunology Therapeutic Area Head, Johnson & Johnson Innovative Medicine. “We are excited about the potential this represents to transform the standard of care for AD, as well as other inflammatory skin diseases involving Th2 inflammation and itch.”.

强生创新医学全球免疫学治疗领域负责人DavidLee表示：“NM26旨在通过针对两种疾病驱动途径来帮助不同的患者亚群，这在治疗AD等异质性疾病时至关重要。”。“我们很高兴这有可能改变AD的护理标准，以及其他涉及Th2炎症和瘙痒的炎症性皮肤病。”。

AD is the most common inflammatory skin disease2. It causes itching and inflammation which are made worse by scratching. It can lead to increased risk of skin infections, skin pain, difficulty sleeping, anxiety, stress, depression and even an increased risk of suicide.

AD是最常见的炎症性皮肤病2。它会引起瘙痒和炎症，而抓挠会使情况恶化。它会导致皮肤感染、皮肤疼痛、睡眠困难、焦虑、压力、抑郁甚至自杀风险增加。

“Nearly three-quarters of people with AD are not achieving remission with currently available treatments3. The unmet need is high, and we must do better for patients,” said Candice Long, Worldwide Vice President, Immunology, Johnson & Johnson. “Our investment in NM26, and other bispecific antibodies, is another important step towards our mission of durable, symptom-free remission for all patients living with immune-mediated diseases.”.

“近四分之三的AD患者在目前可用的治疗中没有达到缓解3。未满足的需求很高，我们必须为患者做得更好，”强生公司免疫学全球副总裁坎迪斯·朗（CandiceLong）说。“我们对NM26和其他双特异性抗体的投资是我们实现所有免疫介导疾病患者持久无症状缓解使命的另一个重要步骤。”。

1 Legal entity, Cilag Holding AG

1法人实体，Cilag控股公司

2 https://pubmed.ncbi.nlm.nih.gov/27690741/

2.https://pubmed.ncbi.nlm.nih.gov/27690741/

3 https://pubmed.ncbi.nlm.nih.gov/27690741/

3.https://pubmed.ncbi.nlm.nih.gov/27690741/

About Atopic Dermatitis

关于特应性皮炎

Atopic dermatitis (AD), also referred to as eczema, is a chronic inflammatory skin disorder affecting more than 9.6 million children and 16.5 million adults in the United States. AD is characterized by an overactive immune system that causes damage to the skin barrier, leaving it dry, itchy, and prone to rashes.

特应性皮炎（AD），也称为湿疹，是一种慢性炎症性皮肤病，影响美国960多万儿童和1650万成年人。AD的特征是免疫系统过度活跃，导致皮肤屏障受损，使其干燥，发痒，并容易出现皮疹。

AD may come and go throughout life and patients can experience severe flares of their disease. The condition can cause poor quality of life by causing social stigma impacting the ability to interact with family and friends, interrupting sleep due to intense itching and/or painful skin, and leading to anxiety, stress and depression with an increased risk of suicide..

AD可能在一生中来来往往，患者可能会经历严重的疾病发作。这种情况会导致社会耻辱感，影响与家人和朋友的互动能力，由于强烈的瘙痒和/或皮肤疼痛而中断睡眠，并导致焦虑，压力和抑郁，从而导致自杀风险增加，从而导致生活质量下降。。

About the agreement

关于协议

Under the terms of the transaction Johnson & Johnson (the Company) has acquired Yellow Jersey Therapeutics which includes the NM26 program, and which was formed through a demerger with Numab. J&J entered a separate agreement with Kaken Pharmaceutical to secure rights in the Asia Pacific Region.

根据交易条款，强生（公司）收购了Yellow Jersey Therapeutics，其中包括NM26计划，该计划是通过与Numab的分拆而形成的。强生与Kaken Pharmaceutical签订了一份单独的协议，以确保其在亚太地区的权利。

In accordance with US GAAP, the transaction is being accounted for as an asset acquisition, resulting in an in-process research and development charge of approximately $1.25B in the third quarter of 2024 and full year Adjusted EPS dilution of $0.56 in 2024 and approximately $0.10 in 2025. The 2024 impact will be reflected in updated guidance at the second quarter earnings call on July 17, 2024..

根据美国公认会计准则，该交易被视为资产收购，导致2024年第三季度的过程中研发费用约为12.5亿美元，2024年全年调整后每股收益稀释率为0.56美元，2025年约为0.10美元。2024年的影响将反映在2024年7月17日第二季度财报电话会议上更新的指导意见中。。

About Johnson & Johnson

关于强生公司

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

。我们在医疗创新方面的优势使我们能够建立一个预防、治疗和治愈复杂疾病的世界，在这个世界上，治疗更加智能，侵入性更小，解决方案更加个性化。通过我们在创新医学和医学技术方面的专业知识，我们拥有独特的优势，可以在今天的所有医疗保健解决方案中进行创新，以实现明天的突破，并深刻影响人类的健康。

Learn more at https://www.jnj.com/ or at www.janssen.com/johnson-johnson-innovative-medicine. Follow us at @JanssenUS and @JNJInnovMed. Janssen Research & Development, LLC and Janssen Biotech, Inc. are both Johnson & Johnson companies..

了解更多信息，请访问https://www.jnj.com/或访问www.janssen.com/johnson-johnson-innovative-medicine。请访问@JanssenUS和@JNJInnovMed。Janssen Research&Development，LLC和Janssen Biotech，Inc.都是强生公司。。

Cautions concerning Forward-Looking Statements

关于前瞻性陈述的注意事项

This press release contains “forward-looking statements” regarding the acquisition of NM26 from Numab. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Cilag Holding AG, Janssen Research & Development, LLC, Janssen Biotech, Inc., and/or Johnson & Johnson.

本新闻稿包含有关从Numab收购NM26的“前瞻性声明”。提醒读者不要依赖这些前瞻性陈述。。如果基础假设不准确或出现已知或未知风险或不确定性，实际结果可能与Cilag Holding AG、Janssen Research＆Development，LLC、Janssen Biotech，Inc.和/或Johnson＆Johnson的预期和预测有很大差异。

Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities of the acquisition may not be realized or may take longer to realize than expected; challenges inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new products; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; economic conditions, including currency exchange and interest rate fluctuations; the risks associated with global operations; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including tax laws and global health care reforms; adverse litigation or government action; change in behavior and pending patterns or financial distress of purchasers of health care services and products; and trends toward health care cost containment.

风险和不确定性包括但不限于：收购的预期收益和机会可能无法实现或可能需要比预期更长的时间才能实现；产品研发固有的挑战，包括临床成功和获得监管批准的不确定性；新产品商业成功的不确定性；制造困难和延误；；经济状况，包括货币汇率和利率波动；与全球运营相关的风险；竞争，包括竞争对手取得的技术进步、新产品和专利；专利面临的挑战；适用法律法规的变更，包括税法和全球医疗改革；不利诉讼或政府行为；医疗保健服务和产品购买者的行为和未决模式或财务困境的变化；以及医疗保健成本控制的趋势。

A further list and descriptions of these risks, uncertainties, and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections ca.

有关这些风险、不确定性和其他因素的更多列表和描述，请参见强生公司截至2023年12月31日财年的10-K表年度报告，包括ca部分。

Non-GAAP Financial Measures

非GAAP财务指标

This press release includes Adjusted EPS, which represents a non-GAAP financial measure. The Company believes that providing this non-GAAP financial measure enhances the Company’s and investors’ understanding of our financial performance. Non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP.

本新闻稿包括调整后的每股收益，这是一项非公认会计原则的财务指标。公司认为，提供这种非GAAP财务指标可以增强公司和投资者对我们财务业绩的理解。非GAAP财务指标不应被视为替代或优于根据GAAP确定或计算的财务指标。

The Company’s definitions of its non-GAAP financial measures may not be comparable to similarly titled measures reported by other companies. The most directly comparable GAAP measure to Adjusted EPS is earnings per share, or EPS. The Company is not providing a reconciliation of Adjusted EPS to EPS, however, because Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis as the Company is unable to predict with reasonable certainty the ultimate outcome of adjusted items, such as legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort.

公司对其非公认会计准则财务指标的定义可能无法与其他公司报告的类似标题的指标进行比较。与调整后每股收益最直接可比的GAAP指标是每股收益（EPS）。然而，公司没有提供调整后每股收益与每股收益的对账，因为强生公司没有提供前瞻性的GAAP财务指标，因为公司无法合理确定地预测调整项目的最终结果，如法律诉讼、异常损益、收购相关费用和采购会计公允价值调整。

These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP..

这些项目是不确定的，取决于各种因素，可能对强生公司根据GAAP计算的结果具有重要意义。。